Prelude Therapeutics Inc(PRLD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Nov 12 at 4:23 PM ET (Korea 11/13 06:23)AI-drawn chart patterns are for reference only.
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.79 | Insider Own | 43.95% | Shs Outstand | 65.0M | Perf Week | -0.98% |
| Market Cap | 0.28B | Forward P/E | - | EPS next Y | -18.41% | Insider Trans | - | Shs Float | 44.7M | Perf Month | 8.98% |
| Enterprise Value | 0.15B | PEG | - | EPS next Q | 0.01 | Inst Own | 45.8% | Short Float | 9.34% | Perf Quarter | -36.58% |
| Income | -0.06B | P/S | 12.53 | EPS this Y | 68.84% | Inst Trans | 18.04% | Short Ratio | 8.58 | Perf Half Y | -21.25% |
| Sales | 0.02B | P/B | 2.1 | EPS next 5Y | 57.36% | ROA | -39.76% | Short Interest | 4.18M | Perf YTD | 21.38% |
| Book/sh | 1.68 | P/C | 1.85 | EPS past 3/5Y | 19.05% 0.15% | ROE | -57.73% | 52W High | -48.46% ($6.83) | Perf Year | 139.46% |
| Cash/sh | 1.9 | P/FCF | - | Sales past 3/5Y | - | ROIC | -40.7% | 52W Low | 171.81% ($1.29) | Perf 3Y | 16.94% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 55.73% | Gross Margin | 92.92% | Volatility(W/M) | 11.22% 8.94% | Perf 5Y | -78.27% |
| Dividend TTM | - | EV/Sales | 6.55 | Sales Y/Y TTM | 220.34% | Oper. Margin | -300.56% | ATR (14) | 0.33 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 4.07 | EPS Q/Q | 65.57% | Profit Margin | -269.75% | RSI (14) | 41.91 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 4.07 | Sales Q/Q | - | SMA20 | -5.42% ($3.72) | Beta | 1.19 | Target Price | $9.2 |
| Payout | - | Debt/Eq | 0.13 | Earnings | 2026/8/11 | SMA50 | -12.79% ($4.04) | Rel Volume | 0.47 | Prev Close | $3.78 |
| Employees | 79 | LT Debt/Eq | 0.11 | EPS/Sales Surpr. | 28.83% - | SMA200 | -13.94% ($4.09) | Avg Volume(3M) | 0.49M | Price | $3.52 |
| IPO | 2020/9/25 | Option/Short | Yes/Yes | Trades | 1884 | Volume | 230,447 | Change | -6.88% |
🧬 A clinical-stage biotech company developing anti-cancer drugs based on targeted protein degradation (degrader) technology. Headquartered in the U.S., it is focused on developing treatments for hard-to-treat cancers through its precision oncology pipeline, including a SMARCA2 degrader and KAT6A/YAK2 programs.
Over the past 1 year, roughly in the middle
48% below its 1-year high.
Traded less than usual. That is 47% of its average volume.
PRLD has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +68.8% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $1,253. Peers typically go for $1,169.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -78.3%. The S&P 500 did +62% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership looks stable
Institutions hold 45.8%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #272 of 597 in the industry
Based on market cap of $281M.
VOGX#271 Vogenx Inc $284M PER - PRLD#272 Prelude Therapeutics Inc $281M PER - 
FULC#273 Fulcrum Therapeutics Inc $281M PER - 
LRMR#274 Larimar Therapeutics Inc $280M PER - 
SABS#275 SAB Biotherapeutics Inc $277M PER - 
FAQ
What kind of company is PRLD?
PRLD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of PRLD?
The market cap of PRLD is approximately $281M, ranking 3,709 within its sector.
What is the 52-week high and low for PRLD?
PRLD has recorded a 52-week high of $6.83 and a low of $1.29.
